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In treatment of severe atopic dermatitis, drugs with carcinogenic potentials are used to manage the disease. We
therefore analyzed whether patients having severe atopic eczema had an increased cancer risk. The study pop-
ulation included all individuals hospitalized in Denmark with a primary diagnosis of atopic dermatitis during 1977–
1996. Follow-up was conducted in 1996 in the Danish Cancer Register. A total of 6275 persons were included.
Among 2030 adult patients, an increased risk of cancer was observed, standard morbidity ratio (SMR)¼ 1.5 (95% CI:
1.2–1.9). Half the excess cases of cancer was keratinocyte carcinomas of the skin diagnosed within the ﬁrst 9 y of
follow–up, SMR¼ 2.4 (95% CI: 1.4–3.9). For men, SMR¼ 2.7 (95%CI: 1.2–5.4). In conclusion, earlier hospitalized
adult atopic dermatitis patients had an increased risk of cancer. Half the excess cases of cancer were keratinocyte
carcinomas. This may be a result of a detection bias or due to the carcinogenic potentials of some of the therapies
of severe atopic dermatitis.
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Atopic dermatitis is a common chronic disease among chil-
dren in industrialized countries (Olesen et al, 1997; Laughter
et al, 2000; Mortz et al, 2001). The immune activation in
atopic dermatitis has been intensively studied (Thestrup-
Pedersen, 1997; Thestrup-Pedsersen et al, 1997; Vest-
ergaard et al, 2000; Volke et al, 2000; Bang et al, 2001;
Higashi et al, 2001; Ringer et al, 2001). Recently, it was
observed that blood and skin-homing lymphocytes in adults
with atopic dermatitis had telomere erosion together with
increased telomerase activity of their T lymphocytes (Wu
et al, 2000), findings that are known to be associated with
almost 90% of all cancers of the hematopoietic system
(Shay and Bacchetti, 1997) including cutaneous T cell
lymphoma (Wu et al, 1999). Also, immunosuppressive
therapies such as ultraviolet (UV) light therapy, tar, and
cyclosporine, a calcineurin inhibitor immunosuppressant
used for a variety of skin diseases including atopic derma-
titis, may increase the risk of cancer (Stern et al, 1979; Stern
and Laird, 1994; Marcil and Stern, 2001; Paul et al, 2003).
We therefore asked if atopic dermatitis is associated with an
increased risk of cancer later in life.
Results
The cohort consisted of 6275 persons eligible for follow-up
for a first cancer. In this group, 4245 were children (o18 y of
age) and 2030 were adults (Table I). Among the children,
only four were found to later develop cancer (none skin
cancers), whereas 9.2 cancers were expected. The reduced
cancer prevalence among children with atopic dermatitis
was not statistically significant. The cohort of children was
therefore not analyzed further. The adults, 779 men and
1251 women, could be followed in the Cancer Register for
6908 and 11,559 y, respectively. Table I shows the adult
atopic dermatitis cohort regarding gender, age, and diag-
nosis period.
Table II shows the results for observed versus expected
cancers and the types of cancers. Persons previously
admitted for atopic dermatitis had a significant increased
risk of cancer development standard morbidity ratio
(SMR)¼1.5 (95% CI: 1.2–1.9). Half of the excess cancers
were skin cancer. We observed 16 skin cancer cases versus
6.6 expected, SMR¼2.4 (95% CI: 1.4–3.9). Eight men de-
veloped skin cancer versus 2.9 expected, SMR¼2.7 (95%
CI: 1.2–5.4), whereas eight women developed skin cancer
versus 3.7 expected, SMR¼2.2 (95% CI: 0.9–4.3). The in-
creased risk for development of skin cancer was statistically
significant 5–9 y after discharge, but decreased to an in-
significant level thereafter (Table III). All skin cancers were
biopsy-proven keratinocyte carcinomas. Table IV shows
characteristics of these individuals. Among men, six cases
of basal cell carcinomas and two cases of squamous cell
carcinomas were found. Among women, seven cases of
basal cell carcinomas and one case of squamous cell car-
cinoma were observed. No cases of melanoma were ob-
served in the adult cohort versus 2.4 expected.
Neither men nor women had an increased risk of other
cancers including lymphoma.The authors have no conflict of interest to disclose.
Abbreviation: SMR, standard morbidity ratio
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Discussion
The main finding of this study is that adults previously ad-
mitted to hospital with atopic dermatitis had an increased
risk of cancer mostly ascribed to a significant increase of
keratinocyte carcinomas among men diagnosed within 9 y
after discharge of the hospital. No cases of malignant me-
lanoma nor lymphomas were observed. Children admitted
for atopic dermatitis had no increased risk of any cancer.
The risk of cancer among atopic dermatitis patients has
not been intensively studied, but a recent case–control
study has observed a lack of relationship between atopic
dermatitis and non-melanoma skin cancer (Ming et al,
2004). This study was based on selecting both cases and
controls among dermatological patients, and a direct com-
parison of the results is not possible. The increased risk of
cancer among our population of patients hospitalized for
atopic dermatitis is consistent with the observed increased
risk of cancer among patients hospitalized for psoriasis in
Sweden (Boffetta et al, 2001). The increased risk of cancer
in patients with psoriasis, however, covered several malig-
nancies, whereas the increase in keratinocyte carcinomas
of the skin contributed to half of the excess number of
cancers among atopic dermatitis patients in Denmark.
The increased risk of keratinocyte carcinomas may have
several explanations. One obvious reason is the carcino-
genic potentials of a variety of different treatments that
hospitalized patients with severe atopic dermatitis receive.
The squamous cell carcinomas among our cases occurred
on sites different from the normally sun-exposed areas of
the body which indicate a causative role of earlier immuno-
suppressive therapy, i.e., UV light treatments and/or tar bath
treatments that are frequently used in Denmark. Only one
study has previously looked at risks for skin cancer among
patients with atopic dermatitis treated with coal tar and UV
light (Goeckerman therapy). The follow-up period for the
426 patients was 25 y, and no increase of skin cancer
was observed compared with the background population
(Maughan et al, 1980).
Psoriasis patients have been more intensively studied for
development of skin cancer. Several studies have observed
an increased risk of non-melanoma skin cancer, especially
squamous cell carcinomas associated with the use of UV
light and PUVA as therapeutic modalities, with an anatom-
ical distribution different from the background population
(Stern et al, 1979, 1998; Stern and Laird, 1994; Frentz et al,
1999; Frentz and Olsen, 1999; Hannuksela-Svahn et al,
2000; Marcil and Stern, 2001; Margolis et al, 2001). UV-light
therapy is increasingly being used in patients with atopic
dermatitis, but it has not been associated with increased
risk of skin cancer (Jekler, 1992).
It is known from patients in immunosuppressive therapy
with calcineurin-inhibitor immunosupressants following or-
gan transplantation or as a treatment for psoriasis that skin
cancer is a very common event, developing within 5–10 y
after initiation of the therapy (Birkeland et al, 1995; Bouwes
Bavinck et al, 1996; Ong et al, 1999; Winkelhorst et al, 2001;
Paul et al, 2003). This demonstrates that immune surveil-
lance mechanisms are important for resistance toward
development of skin cancer. Studies among children and
adults in immunosuppressive therapy following organ trans-
plantation indicate that those developing skin cancers have
a history of sun-damaged skin, meaning that the rise of skin
cancer is a consequence of a carcinogenic impact followed
Table I. Demographic data for persons in the Danish
atopic dermatitis (AD) cohort 1977–1996, 18 y or older at ﬁrst
hospitalization
No. men (%) No. women (%)
779 (100.0) 1251 (100.0)
Age at AD
18–29 456 (58.5) 859 (68.7)
30–39 142 (18.2) 200 (16.0)
40–49 78 (10.0) 107 (8.6)
50–59 38 (4.9) 45 (3.6)
60–69 37 (4.7) 24 (1.9)
70þ 28 (3.6) 16 (1.3)
Period of AD
1977–1981 163 (20.9) 249 (19.9)
1982–1986 193 (24.8) 324 (25.9)
1987–1991 231 (29.7) 385 (30.8)
1992–1996 192 (24.6) 293 (23.4)
Table II. Number of observed and expected ﬁrst cancers and
standard morbidity ratio (SMR) with 95% conﬁdence intervals
in Danish adult atopic dermatitis cohort, 1977–1996
Observed Expected SMR (95% CI)
All cancer 67 44.3 1.5 (1.2–1.9)
Digestive organs 7 6.4 1.1 (0.4–2.2)
Respiratory system 8 4.6 1.7 (0.7–3.4)
Breast cancer 10 6.9 1.4 (0.7–2.7)
Female genital organs 10 4.6 2.2 (1.0–4.0)
Male genital organs 6 2.6 2.3 (0.8–5.0)
Keratinocyte carcinomas 16 6.6 2.4 (1.4–3.9)
Lymphatic and
hematopoitic tissue
4 2.9 1.4 (0.4–3.5)
Other cancer 6 9.7 0.6 (0.2–1.3)
Table III. Relative risk of keratinocyte carcinomas by follow-up
time in the Danish cohort of adult atopic dermatitis patients,
1977–1996
Follow-up
time (y) Observed Expected Relative risk 95% CI
0–4 6 2.4 2.5 0.9–5.5
5–9 8 2.1 3.8 1.6–7.4
 10 2 2.1 0.9 0.1–3.4
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by immunosuppression (Birkeland et al, 1995; Bouwes Bav-
inck et al, 1996; Ong et al, 1999; Winkelhorst et al, 2001).
The increased risk of keratinocyte carcinomas among the
Danish adult patients hospitalized with atopic dermatitis
may be due to the carcinogenic potential of immunosup-
pressive therapies that they have received over the years.
But, we lack information on the treatments the individual
patients in this cohort underwent.
Detection bias is another plausible explanation of the
increased risk of non-melanoma skin cancer observed
among atopic dermatitis patients. The skin of a patient
with chronic relapsing atopic dermatitis is often examined
by a phycisian trained in discovering skin cancer, which
increases the chance of discovering cancer of the skin
compared with individuals of the general population.
Diagnostic misclassification might be another problem.
The Danish National Hospital register recieves information
from the hospital departments and out-patient clinics every
month (Andersen et al, 1999). We included the patients with
a primary diagnosis of atopic dermatitis all hospitalized in
dermatological or pediatric departments, and we therefore
suspect that misclassification is a minor problem.
The results are not applicable to all atopic dermatitis
patients as the majority of patients are not hospitalized
because of their skin disease. In Denmark, admission to a
hospital for atopic dermatitis is free of charge for the pa-
tient, but it can only take place after referral by a doctor. It is
most likely that the adult patients with atopic dermatitis
included in our study represent severe chronical cases,
whereas hospitalization of infants and children with atopic
dermatitis may have a variety of reasons like anxiety and
compliance problems of the parents.
Two case reports have described non-Hodgkin lymph-
oma (Lange-Vejlsgaard et al, 1989), and Se´zary’s syndrome
(Van Haselen et al, 1999) in patients with severe atopic der-
matitis. Despite the findings that lymphocytes among this
group of patients show telomere erosion (Wu et al, 2000),
we found no increased risk for lymphoma.
The lack of melanoma among atopic dermatitis patients
may be due to a chance finding; however, it is consistent
with the finding by Birkeland et al (1995) on transplant pa-
tients and Broberg and Augustsson (2000), who observed
significantly fewer nevi among atopic patients compared
with non-atopic controls (Broberg and Augustsson, 2000).
The mechanisms behind this observation are so far un-
known.
In conclusion, adult atopic dermatitis patients had an
increased risk of cancer. Half the excess cases of cancer
were keratinocyte carcinomas diagnosed within 9 y of dis-
charge from hospital. This may be due to the carcinogenic
potentials of the therapies used for severe atopic dermatitis
or to a detection bias. We plan to perform a comparative
10-y follow-up study of hospitalized adult atopic dermatitis
patients, and suggest further studies of the cancer risk
among atopic dermatitis patients, including detailed infor-
mation on the clinical aspects of the disease and the treat-
ments the individual underwent.
Subjects and Methods
Participants The study cohort consisted of all patients hospital-
ized at least once in Denmark between 1977 and 1996, inclusive of
a primary diagnosis of atopic dermatitis. The patients were iden-
tified in the Danish National Hospital Register (Andersen et al,
Table IV. Types of skin cancer and location in Danish adult atopic dermatitis patients
Patient Gender Age at cancer (y) Timea (mo) Diagnosisb Tumor location
1 F 55 98 BCC Trunk
2 F 45 50 BCC Trunk
3 F 39 154 BCC Lip
4 F 53 32 BCC Lip
5 F 51 61 BCC Face
6 F 49 194 BCC Multiple sites
7 F 57 67 BCC Multiple sites
8 M 59 102 BCC Face
9 M 74 13 BCC Face
10 M 60 77 BCC Face
11 M 44 40 BCC Face
12 M 49 118 BCC Face
13 M 48 79 BCC Face
14 F 53 3 SCC Upper limb
15 M 60 88 SCC Trunk
16 M 52 18 SCC Multiple sites
aTime from admission to hospital with atopic dermatitis to diagnosis of skin cancer.
bBiopsy proven.
M, male; F, female; BCC, basal cell carcinoma; SCC, squamous cell carcinoma.
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1999) and followed up for cancer in the Danish Cancer Register
(Storm et al, 1997), and for emigration, disappearance, and death
in the Central Population Register (CPR) through 1996. Since April
1, 1968, all residents in Denmark have been assigned a unique
personal identification number by CPR. Every branch of the public
administration is obliged to use this number and it serves as an
efficient key for linkage of data for the individual.
Trial registries: This study was approved by the Ethics Com-
mittee of the County of Aarhus, Lyseng Alle´ 1, DK-8000 Aarhus C,
Denmark; Ref number: 2000-2.0/3 and by the Danish Data
Protection Agency, Christians Brygge 28, 1559 Copenhagen V,
Denmark; Ref number: 1999-1200-563.
The Danish National Hospital Register holds information on all
discharges from Danish somatic hospitals from 1977 onward. In-
formation includes identity of the patient by CPR number, date of
discharge, primary diagnosis and supplementary diagnoses during
the hospital stay, and identification of the department in the hos-
pital (Andersen et al, 1999).
Since 1943, practically all cancer cases in Denmark have been
notified in the Danish Cancer Register, and the register is con-
sidered to be 95%–98% complete (Storm et al, 1997).
A total of 10,398 admissions of 6563 individuals took place from
1977 to 1996, with the primary diagnosis of atopic dermatitis. The
primary diagnosis indicates the cause of admission to the hospital,
and the disease is diagnosed by specialists in Dermatology or
Paediatrics. From 1977 to 1993, these patients were coded in the
Danish National Hosptial Register according to the ICD-8 classi-
fication and according to the ICD-10 classification from 1994
onwards. Persons recorded with an invalid personal registration
number or not living in Denmark were excluded, leaving 6305 per-
sons to be followed up in the Danish Cancer Register. The obser-
vation period for cancer development for each patient started from
the first admission with atopic dermatitis and the persons were
followed to the first event of cancer, emigration, or death, on De-
cember 31, 1996. A total of 30 persons were already registered in
the Cancer Register before their admission for atopic dermatitis
and nine of these had skin cancer. These patients were omitted for
further analysis. We restricted the detailed analysis to the adult
cohort: 2030 persons aged 18 y or above at the first hospitalization
with atopic dermatitis.
Statistical analysis For this cohort, the observed and the ex-
pected number of cancer cases were calculated, in addition to the
ratio between the observed and the expected, hereafter called the
SMR. The expected numbers of cancer cases were estimated by
summing up the years under risk of cancer in the cohort and mul-
tiplying these with the incidence rates of cancer for the Danish
population in 5-y age- and period-specific groups for each sex.
Further analysis of the relative risk of keratinocyte carcinomas for
the cohort compared with the risk in the Danish population used
Poisson regression methods to analyze the SMR as a function of
age, calendar period, and time since the first hospital diagnosis of
atopic dermatitis, with the number of cases of keratinocyte car-
cinomas as the outcome and the logarithm of the expected
number as the offset.
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